Concepedia

Ming Chang

MC

Statistics

Publications

37

Citations

1.9K

H-Index

22

Active since

1991

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Germany)

Bristol-Myers Squibb (Sweden)

Karolinska Institutet

Karolinska University Hospital

Ming Chang is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, pharmacy, and clinical pharmacology.

ORCID

Publications per year

1991–2025

37

Publications

37

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis

Xiaoli Wang, Giridhar Tirucherai, Thomas Marbury et al. · The Journal of Clinical Pharmacology · 2015 · 284 citations · Full text

, , +17

Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype

Ming Chang, Marja-Liisa Dahl, Gunnel Tybring et al. · Pharmacogenetics · 1995 · 203 citations

, , +13

Interphenotype differences in disposition and effect on gastrin levels of omeprazole—suitability of omeprazole as a probe for CYP2C19.

Ming Chang, Gunnel Tybring, M-L Dahl et al. · British Journal of Clinical Pharmacology · 1995 · 184 citations · Full text

, , +17

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban

Ming Chang, Zhigang Yu, Andrew Shenker et al. · The Journal of Clinical Pharmacology · 2015 · 172 citations

, , +17

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co‐transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus

Sreeneeranj Kasichayanula, Ming Chang, Mayumi Hasegawa et al. · Diabetes Obesity and Metabolism · 2011 · 115 citations

, , +17

1–5 of 37